查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
MSL 指標：衡量成功的整體方法
市場調查報告書
商品編碼
1773136

MSL 指標：衡量成功的整體方法

MSL Metrics: A Holistic Approach to Measuring Success
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入探討了製藥業醫學科學聯絡（MSL）指標的複雜性，並對用於評估 MSL 績效的定量和定性指標進行了全面分析。報告強調了製定符合策略業務目標並推動利害關係人參與的有效指標所面臨的挑戰和機會。將深入了解混合工作模式對 MSL 活動的影響、數位平台在指標收集中的作用，以及將指標置於具體情境中以反映 MSL 的真正價值的重要性。本報告也探討了第三方基準測試的潛在優勢和局限性，並強調了醫學事務團隊在領導指標制定和溝通方面的關鍵作用。對於尋求最佳化 MSL 績效評估並將其融入更廣泛的組織策略的製藥專業人士來說，這份資源非常重要。

關鍵問題

  • 1.目前使用哪些定量和定性指標來評估 MSL 績效？
  • 2.MSL 如何看待這些指標的有效性和相關性？
  • 3.公司在製定和採用有意義的MSL 指標方面面臨哪些挑戰？
  • 4.新冠疫情後向混合工作模式的轉變對 MSL 敬業度指標有何影響？
  • 5.MSL 在指標的選擇與採用上扮演什麼角色？
  • 6.公司如何將 MSL 指標與更廣泛的醫療事務和商業策略結合？
  • 7.使用第三方 MSL 績效基準測試的潛在優點和缺點是什麼？
  • 8.除了量化指標之外，如何制定定性指標來捕捉 MSL 的更廣泛影響？
  • 9.數位平台在收集和呈現 MSL 指標方面可以發揮什麼作用？
  • 10.醫療事務團隊如何在其組織內引領 MSL 指標的情境化與溝通？

主要公司

  • Betterworks
  • Excel
  • H1 platform
  • Microsoft Teams
  • SharePoint
  • Zoom
  • X Spaces（原名：
    Twitter Spaces）

部分參與專家名單

  • 總部位於法國的製藥公司的MSL
  • 德國BioMarin製藥公司資深MSL
  • 義大利一家生物製藥公司的醫學科學主管
  • 西班牙一家2024年全球銷售額排名前20的製藥公司的高級MSL
  • 英國GSK的MSL
  • 美國Teva Pharmaceuticals全球醫學合作副總裁

方法論：

調查報告是基於獨立而簡潔的分析，這些分析源自於專有的產業研究以及對產業意見領袖的深入訪談。報告深入分析了製藥公司高層需要了解的關鍵趨勢和市場發展，以應對未來的機會和挑戰。每份報告的重點都透過對二手文獻的回顧和已識別的知識差距來確定。基於這些初步研究，創建了基於證據、專家指導的討論指南，以確保調查能回答最重要的問題。此外，制定了嚴格的篩選標準，以確保受訪者有足夠的經驗、知識和資格就相關主題發表意見。

報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，致力於製藥業，為生物製藥專業人士和決策者提供詳盡且切實可行的洞察。深厚的行業知識使能夠提供相關且有價值的洞察，幫助掌握新興趨勢，有效應對複雜挑戰。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖（KOL）的獨立、公正的見解，報告能夠提供所需的準確性和可靠性。獨家獲取其他地方無法獲得的採訪和資料，以及持續的市場監測，讓全面了解市場動態。報告涵蓋 40 多個活躍的疾病領域，提供包括關鍵意見領袖洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入和其他領域問題的看法，使能夠做出更明智的資料驅動決策，在快速變化的行業中保持競爭力。

簡介目錄

This report delves into the intricacies of Medical Science Liaison (MSL) metrics within the pharmaceutical industry, providing a comprehensive analysis of both quantitative and qualitative measures used to evaluate MSL performance. It addresses the challenges and opportunities in developing meaningful metrics that align with strategic business goals and enhance stakeholder engagement. Gain insights into the impact of hybrid working models on MSL activities, the role of digital platforms in metric collection and the importance of contextualising metrics to reflect the true value of MSLs. The report also explores the potential benefits and limitations of third-party benchmarking and highlights the critical role of medical affairs teams in leading metric development and communication. This resource is essential for pharmaceutical professionals seeking to optimise MSL performance evaluation and integration into broader organisational strategies.

Key Questions Answered:

  • 1. What are the current quantitative and qualitative metrics used to evaluate MSL performance?
  • 2. How do MSLs perceive the effectiveness and relevance of these metrics?
  • 3. What challenges do companies face in developing and implementing meaningful MSL metrics?
  • 4. How has the shift to hybrid working models post-COVID-19 impacted MSL engagement metrics?
  • 5. What role do MSLs play in shaping the choice and application of metrics?
  • 6. How can companies ensure that MSL metrics align with broader medical affairs and business strategies?
  • 7. What are the potential benefits and drawbacks of using third-party benchmarking for MSL performance?
  • 8. How can qualitative metrics be developed to capture the broader impact of MSLs beyond quantitative measures?
  • 9. What is the role of digital platforms in collecting and presenting MSL metrics?
  • 10. How can medical affairs teams lead in the contextualisation and communication of MSL metrics within the organisation?

Key Companies:

  • Betterworks
  • Excel
  • H1 platform
  • Microsoft Teams
  • SharePoint
  • Zoom
  • X Spaces (formerly known as
    Twitter Spaces)

Partial List of Participating Experts:

  • An MSL at a pharmaceutical company, based in France.
  • A Senior MSL at BioMarin Pharmaceutical, based in Germany.
  • A Medical Science Lead at a biopharmaceutical company, based in Italy.
  • A Senior MSL at a pharmaceutical company in the top 20 by global sales in 2024, based in Spain.
  • MSL at GSK, based in the UK.
  • Global Vice President, Medical Engagement at Teva Pharmaceuticals, based in the US

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.